BSX Boston Scientific Corp.
Boston Scientific Corp. (BSX) trend channel, buy level and 3-month target on Trade The Path. Sector: Healthcare. Listed on NYSE. Levels below are fitted to this ticker's own swing highs and lows (Theil–Sen, log-price), then projected 3 months. If this ticker has no settled sample yet, treat the numbers as a geometric read, not a track record. Information only, not financial advice.
Mid-channel (provisional)
Price is between the two trend lines. Nothing to act on yet.
Read from the last 12 months of history we hold: falling, drifting −64% a year. The nearest ceiling overhead is US$47.82. What would overturn this: a close below US$41.99 — the floor of the channel being read — after which the trend, not the entry, is what was wrong.
- 12 months read from
- US$41.99 – US$47.82 Falling channel, −64% a year
- Position in that channel
- 33% 0% at the floor, 100% at the ceiling
Provisional: fitted to a short history, so treat the lines as a first read rather than a projection. No trade is suggested and alerts stay off until there is more data.
What broke this trend
- The fall
- -61% from US$108.188 Sept 2025 → 14 July 2026
- Whose problem it was
- This company0 of 1 Surgical & Medical Instruments & Apparatus peers fell with it
- Does it resolve?
- Unsettled too close to a coin toss on the record to call
- Regained so far
- 2%of what it lost
- What the record says
- 54% of 508 comparable falls came back, typically in 145 days measured across every stock we hold history for, its peer group being too small
The trend broke in September 2025: price fell 61% from 108.18 to 42.63 by July 2026, and has regained 2% of that fall since. Its peers did not fall with it, so this was about the company rather than its sector. The wire that week: “Oppenheimer Upgrades Boston Scientific to Outperform, Raises Price Target to $125”. What happens next is not settled: falls of about 61% here have come back to the old high 54% of the time (508 comparable falls), typically in 145 days, which is too close to a coin toss to price a recovery from.
Reported at the time: Oppenheimer Upgrades Boston Scientific to Outperform, Raises Price Target to $125 — 8 Sept 2025
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line (12 months)
- Lower trend line (12 months)
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
The lines above are fitted to a short history, which is not a base we will project a published call from. The buy and target below are still this site's read of those lines.
Buy at or below
US$37.87
level as at 17 Sept 2026
Our target
US$41.99
by 16 Dec 2026
Projected move
10.9%
gross, before costs
Price is at or through our target.
- Upper line touches
- 5
- Lower line touches
- 3
- Fit confidence
- 44%
- Fitted
- 16 Sept 2026
Company information
Fundamentals are not available for this instrument from the current data provider.
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.